(Bloomberg) WuXi Biologics Cayman Inc. shares slumped for the second day as investors worried over a ramp-up in geopolitical tensions following a US draft bill targeting Chinese biotech companies.Most Read from BloombergTraders Line Up for ‘Once-in-a-Generation’ Emerging Markets BetSingapore’s $200,000 Toyotas Fuel Angst Over Wealth GapHouthi Hit on Russian Fuel Has Traders Recalculating RisksThree US Troops Killed in Attack Tied to Iran-Backed GroupsTrump’s Cash Stockpile at Risk From $450 M
(Bloomberg) WuXi Biologics Cayman Inc. shares slumped for the second day as investors worried over a ramp-up in geopolitical tensions following a US draft bill targeting Chinese biotech companies.Most Read from BloombergTraders Line Up for ‘Once-in-a-Generation’ Emerging Markets BetBlackstone Is Building a $25 Billion Empire of Power-Hungry Data CentersTrump Cash Stockpile at Risk From $450 Million Dual VerdictsMusk Says First Human Patient Has Received Brain ImplantAmazon Drops iRobot Deal;
(Bloomberg) WuXi Biologics Cayman Inc. shares slumped for the second day as investors worried over a ramp-up in geopolitical tensions following a US draft bill targeting Chinese biotech companies.Most Read from BloombergTrump Risks Losing More Than Half of Swing-State Voters If Found GuiltyMusk’s $55 Billion Pay Package Voided, Threatening World’s Biggest FortuneS&P 500 Has Its Worst Fed-Decision Day Since March: Markets WrapByron Allen’s Latest Takeover Bid: Paramount for $14 BillionNY Commu
‘TECHNOLOGY TRANSFER’: A company executive said it set up a subsidiary in Taiwan to cooperate with local hospitals and regulators directly to provide vaccinesBy Kao Shih-ching / Staff reporter
US biotechnology company Moderna Inc, one of the two leading makers of mRNA vaccines for COVID-19, on Tuesday announced that it would establish four subsidiaries in Taiwan, Hong Kong, Malaysia and Singapore to support delivery of its vaccines and therapeutics.
The subsidiary in Taiwan is expected to be set up by the end of this year, Moderna told Chinese-language media, adding that it would recruit local talent and collaborate with local hospitals on clinical trials.
Moderna has signed a contract with Taiwan to offer 20 million COVID-19 vaccine and booster doses this year, and another 15 million next year, the company said